Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
📧 Sign up to get email alerts when something new happens for Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas [Phase 2]
Clinical trial update indicates a Phase 2 study of the JAK1 inhibitor golidocitnib for relapsed/refractory indolent T- and NK-cell lymphomas…